Retinal Capillary Hemangioma Treated with Verteporfin Photodynamic Therapy and Intravitreal Triamcinolone Acetonide by Suh, Shin Cho et al.
178
Received: January 26, 2007    Accepted: August 6, 2007
Reprint requests to Seon Hee Bae, MD. Department of Ophthal- 
mology, Konyang University Hospital, 685 Gasoowon-dong, Seo-gu, 
Daejeon, 302-718, Korea. Tel: 82-42-600-8816; Fax: 82-42-600-9176, 
E-mail: ophthal73@hanmail.net
* This paper was presented as a poster at the 96th annual meeting 
of the Korean Ophthalmological Society in November 2006.
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Purpose: To report a case of retinal capillary hemangioma treated with verteporfin photodynamic therapy 
combined with intravitreal triamcinolone acetonide.
Methods:  A 15-year-old female presented with metamorphopsia in the left eye for 7 days. Examination 
showed peripheral endophytic retinal capillary hemangioma, macular edema, and a best-corrected visual 
acuity of 20/50. The hemangioma and macular edema were treated with verteporfin photodynamic therapy 
and intravitreal triamcinolone acetonide.
Results: After 5 months of follow-up, involution of the hemangioma, reduction of macular edema, decrease 
of the feeder and draining vessel diameter, and improvement of best-corrected visual acuity to 20/25 was 
seen.
Conclusions: This verteporfin photodynamic therapy combined with intravitreal triamcinolone acetonide 
appeared to cause involution of the hemangioma with reduction in macular edema and improvement in 
visual acuity.
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Retinal capillary hemangioma (RCH) is an uncommon 
benign vascular tumor of the retina that can occur 
sporadically or in association with von Hippel-Lindau (VHL) 
syndrome. It was first described by Fuchs in 1882.
1-3  RCH 
is the most frequent and the earliest manifestation of VHL 
disease. Therefore, an ophthalmologist is frequently 
involved in the care of patients with VHL.
4 I t  i s  n o t  c l e a r  
whether RCH that occurs without a family history
5 is most 
commonly sporadic or most commonly represents an initial 
manifestation of VHL.
6,7 RCH lesions often lead to visual 
loss secondary to hemorrhage into the vitreous, retina, or 
subretinal space. They can also lead to macular edema or 
exudative retinal detachment.
8 Various forms of therapy have 
been attempted, but all have inherent problems with efficacy 
or with side effects such as transiently increased exudation 
or epiretinal membrane formation.
8 A wide variety of 
treatment methods have been described for angiomatous 
lesions of the retina.
8 Laser photocoagulation is effective for 
small angiomatous proliferations but is not effective for large 
lesions, particularly those associated with pronounced 
exudation and hemorrhage.
8 Even without overlying media 
opacity, thermal laser photocoagulation probably has a 
limited depth of treatment, leaving a large amount of viable 
and potentially problematic vessels.
9 Cryotherapy may be 
more effective in eventually closing the vessels in thicker 
lesions, but this treatment is associated with a transient 
increase in the amount of exudation present.
10 Radiation 
therapy has been used, but it has the potential for causing 
significant long-term complications. Photodynamic therapy 
(PDT) with verteporfin has been used for the treatment 
of choroidal neovascularization in age-related macular 
degeneration.
10 When activated, verteporfin appears to cause 
oxidative damage to the vascular endothelial cells.
9 This 
damage leads to vascular occlusion, although the surrounding 
tissue is preserved.
8
We report the first case of retinal capillary hemangioma 
treated with verteporfin photodynamic therapy combined with 
intravitreal triamcinolone injection.
Case Report
A 15-year-old female presented with metamorphopsia in 
the left eye for 7 days. Her best-corrected visual acuity SC Suh, et al. RETINAL CAPILLAR HEMANGIOMA TREATED WITH PDT
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Fig. 1. First visit (pre-treatment). (A) The left fundus reveals mild macular edema and hard exudates with tortuous dilated vessel. (B)
Circumscribed endophytic retinal capillary hemangioma appears at the 5 o'clock periphery with a prominent dilated and tortuous 
feeding artery and draining vein. (C, D) Progressive and complete filling of the hemangioma and the retinal vein becomes prominent.
(E) OCT image demonstrating cystic macular edema at first visit. (F) B-scan shows a well-demarcated endophytic retinal lesion 
without choroidal effects.
(BCVA) was 20/20 in the right eye and 20/50 in the left eye. 
The intraocular pressure was within normal limits bilaterally, 
and the results of anterior segment examinations were 
unremarkable. The right fundus was normal. The left fundus 
revealed mild macular edema and hard exudates (Fig. 1A). 
At the 5 o'clock periphery lay a circumscribed exophytic 
retinal capillary hemangioma approximately 2.5 disc diameter 
(DD) with a prominent dilated and tortuous feeding artery 
and draining vein (Fig. 1B). Fluorescein angiography was 
performed, and fluorescein was evident in the dilated feeder 
arteriole (Fig. 1C ,1D). The retinal tumor had fine capillary 
filling, which rapidly became homogeneous (Fig. 1C). 
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Fig. 2. Optical coherence tomogram images. (A) OCT image demonstrating cystic macular edema at first visit. (B) Worsened cystic
macular edema after PDT treatment. (C) 12 days after PDT, improvement of cystic intraretinal edema after intravitreal triamcinolone
acetonide.  (D) 22 days after PDT, OCT image of the forvea shows restoration of the foveal contour.
The drainage vein became prominent in the venous phase, 
while the tumor demonstrated progressive hyperfluorescence 
with late leakage of dye into the surrounding structures (Fig. 
1C). Optical coherence tomogram (OCT) of the fovea 
demonstrated cystic intraretinal edema (Fig. 1E). 
B-scan ultrasonography demonstrated a well-demarcated 
exophytic retinal lesion without choroidal effects (Fig. 1F). 
The patient had no family history of ocular or systemic 
disease. Since retinal capillary hemangioma seemed a likely 
diagnosis, a systemic examination for VHL syndrome - 
including magnetic resonance imaging of the brain, 
abdominal computed tomography scan, and urine tests for 
catecholamines - was performed. Results were negative. 
Genetic testing for VHL syndrome was not performed.
Three days after initial PDT, intravitreal triamcinolone 
(IVTA) was planned. Verteporfin photodynamic therapy was 
performed using 6 mg/m
2 body surface area (BSA) of 
intravenous verteporfin delivered over 10 minutes. Fifteen 
minutes after the start of infusion, a laser light at 689 nm 
delivered 50 J/cm
2 at an intensity of 600 mW/cm
2 over 83 
seconds using a spot size of 7500 µm directed to the 
hemangioma with a Mainster widefield contact lens.
10
Three days after PDT, the patient returned to the hospital 
for IVTA. BCVA declined to 20/160 in the left eye and 
cystic intraretinal edema worsened, shown by optical 
coherence tomogram of the fovea (Fig. 2B). A pre-injection 
single drop of povidone-iodine (5%) solution was applied to 
the eye followed by thorough cleaning of the eyelashes and 
application of a lid speculum. 0.5% proparacaine 
hydrochloride drops (Alcaine
Ⓡ, Alcon) was applied topically. 
Triamcinolone acetonide in a single-use bottle (40 mg/ml, 1 
ml bottle) was drawn into a 1-cc tuberculin syringe after 
cleansing the top of the bottle with an alcohol wipe. A 
separate 30-gauge needle was placed onto the syringe, which 
was then inverted to remove air bubbles. The excess 
triamcinolone was discarded until 0.1 ml (4 mg) remained in 
the syringe. The stab was given 3.5 mm from the limbus (pas 
plana) in the inferotemporal quadrant. The needle was 
removed simultaneously with the application of a cotton- 
tipped applicator over the entry site to prevent regurgitation 
of the injected material. Indirect ophthalmoscopy was used to 
check for central retinal artery (CRA) pulsation, a drop of 
topical antibiotic solution was administered, and the eye was 
patched. The patient was put on a post-injection course of 
topical antibiotic eye drops for a week.
Twelve days after PDT, BCVA had improved to 20/100 
in the left eye and the retinal capillary hemangioma had 
undergone partial involution (approximately 2.5 DD). The 
feeder and draining vessel diameters had decreased by 
approximately 50% and 30%, respectively (Fig. 3A). Optical 
coherence tomogram of the fovea demonstrated improvement 
of cystic intraretinal edema (Fig. 2C).
Twenty-two days after PDT, BCVA had improved to 
20/40 in the left eye and the retinal capillary hemangioma 
had regressed approximately 1.5 DD. The feeder and draining 
vessels were straighter but the diameter remained the same 
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Fig. 3. 12 days after PDT. (A) The feeder and draining vessel diameters decreased. (B) The retinal capillary hemangioma underwent
partial involution (approximately 2.5 DD). The whitish mass is triamcinolone acetonide.
(Fig. 4A). Fluorescein angiography demonstrated decreased 
early filling and late leakage of the hemangioma (Fig. 4C). 
The optical coherence tomogram demonstrated restoration of 
the foveal contour (Fig. 2D).
Three months after PDT, BCVA had improved to 20/30 
in the left eye and the retinal capillary hemangioma had 
regressed approximately 1.0 DD (Fig. 5B). The macular hard 
exudate and edema had improved (Fig. 5A).
Five months after PDT, BCVA had improved to 20/25 in 
the left eye and the macular hard exudates had disappeared 
(Fig. 6A). Regular follow-up of the patient is planned.
Discussion
Retinal capillary hemangiomas (RCH) are capillary 
angiomatous harmatomas of the retina and optic nerve head.
4 
Capillary hemangioma (angiomatosis retinae) of the retina 
occurs in two ophthamoscopically distinct forms: the 
peripheral lesion (known as the von Hippel tumor) and the 
juxtapapillary tumor.
4 These tumors can occur anywhere in 
the fundus, although most commonly they are peripheral and 
endophytic.
9 Either type of tumor may be either an isolated 
retinal vascular abnormality or one of the many systemic 
abnormalities in von Hippel-Lindau disease (VHL).
4
Regardless of systemic association, the retinal tumors 
appear identical clinically and histopathologically.
4 But 
patients with solitary retinal capillary hemangioma present a 
serious dilemma because RCH may or may not be associated 
with VHL disease. In a recent study, the probability of VHL 
disease in patients with solitary retinal capillary hemangioma 
was mathematically estimated to be 30% to 46%, but it 
varied from 45% in the preteen patients to less than 1% in 
those over 60 years old.
11,12 Because the patient described in 
this paper is a young woman who showed peripheral 
exophytic retinal capillary hemangioma, she must be 
regularly and systemically examined for VHLsyndrome.
Most RCH progressively enlarge and there is progressive 
subretinal exudation, frequently leading to total retinal 
detachment and eventual blindness.
13 Therefore, early 
detection and treatment of RCH is associated with good 
visual outcome.
14 In general, the decision to treat RCH and 
the method of management is determined by the size, 
location, and associated findings, such as the extent of 
subretinal fluid, evidence of retinal traction, and overall effect 
or threat of clinical findings on the visual potential of the 
eye.
2 Most commonly, RCH is managed by observation, laser 
photocoagulation, cryotherapy, plaque radiotherapy, and 
vitreoretinal surgery.
2 All treatment options were discussed in 
detail with the patient. Because of the risk of hemorrhage and 
proliferative vitreoretinopathy with cryotherapy, and the 
limitations of laser photocoagulation in the presence of a large 
hemangioma with extensive subretinal fluid, vertepofin 
photodynamic therapy (PDT) was offered to the patient. The 
successful use of PDT in RCH has been reported by several 
authors.
8,10 Atebara described three sessions of PDT for RCH 
in one patient, which resulted in decreased leakage during 
fluorescein angiography, but did not mention the degree of 
the tumor involution.
10 Rodriguez-Coleman et al. reported 
two patients treated with PDT who showed marked and rapid 
regression of the angiomatous proliferation of vessels, but 
made no mention of the change in tumor size.
8
Verteporfin PDT in the treatment of exudative RCH has 
theoretical advantages over conventional treatments of laser 
photocoagulation and cryotherapy.
15,16 But the use of direct 
photocoagulation can potentially cause hemorrhage and 
exudative retinal detachment (ablatio fugax).
4,17,18 On the 
other hand, the infrared-wavelength laser of PDT effectively 
penetrates through subretinal fluid and deeper into a large 
hemangioma than does laser photocoagulation.
19 PDT may be 
less likely to result in hemorrhage and PVR than would 
cryotherapy.
19 PDT actually represents the combination 
of pharmacologic therapy and laser-based therapy.
20 
Photosensitizers have biophysical properties well- suited to 
the thrombotic closure of abnormal neovascularization while 
preserving normal physiologic vessels.
20
Photosensitizers also bind selectively to abnormal 
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Fig. 4. 22 days after PDT. (A) The left fundus reveals decreased macular edema and hard exudates with a straighter vessel. (B) The
retinal capillary hemangioma regressed approximately 1.5 DD. (C, D) Fluorscein angiogram demonstrating decreased early filling and
late leakage of the hemangioma. (E) B-scan showing decreased endophytic retinal lesion.
neovascularization, the vessels of which express more 
lipoprotein receptors than do normal mature vessels.
20
During this patient's therapy, a temporary increase in 
macular exudation occurred after PDT, but other 
complications such as exudative retinal detachment were not 
found. Intravitreal triamcinolone acetonide was performed as 
a treatment for the increased exudation, whether the vascular 
tumor itself or the PDT caused the increase.
21
Corticosteroids have a significant anti-angiostatic 
capacity.
22 The primary mechanism of action of angiostatic 
steroids appears to be in aiding breakdown and blockage of 
the formation of capillary endothelial basement membranes.
22 
Triamcinolone acetonide appears to modulate the 
permeability and adhesion of human choroidal endothelial 
cells in culture.
23 Penfold et al. demonstrated that 
cytokine-induced expression of intracellular adhesion 
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Fig. 5. 3 months after PDT. (A) The macular hard exudate and edema improved. (B) The retinal capillary hemangioma regressed
approximately 1.0 DD.
Fig. 6. 5 months after PDT. (A) The macular hard exudate and edema nearly disappeared. (B) Fluorescein angiogram demonstrating 
reduced fluorescence and leakage associated with the lesion.
molecule-l is down-regulated by triamcinolone acetonide.
23 
Wang et al. demonstrated that matrix metalloproteinases were 
down-regulated following incubation with triamcinolone, 
suggesting that the active remodeling of the extracellular 
matrix necessary for neovascularization can be inhibited.
24 
Ciulla et al. showed that intravitreal triamcinolone acetonide 
completely inhibited laser-induced choroidal novascularization 
in rats.
25 These experiments provide rationale for using 
triamcinolone acetonide to treat choroidal neovascularization 
in exudative macular degeneration and other retinal vascular 
diseases. RCH is a benign vascular tumor of the retina;
1-3 
therefore, the rationale for this approach is to decrease the 
number of photodynamic treatments by combining the 
angiostatic properties of triamcinolone aetonide with the 
vascular occlusion induced by ocular PDT.
In this report of a single case of retinal capillary 
hemangioma with short follow-up, verteporfin PDT combined 
with intravitreal triamcinolone acetonide appeared to cause 
involution of the hemangioma with reduction in macular 
edema and improvement in visual acuity. The authors believe 
the treatment modality used in this case was more effective 
than verteporfin PDT alone would have been.
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